公众号 / 文章中毒与环境急症消化、代谢与肾脏急症

皮下注射溴莫尼定致全身毒性经纳洛酮成功救治

Systemic toxicity from subcutaneous brimonidine injection successfully treated with naloxone.
PubMed 文献 · Am J Emerg Med · 2022-07-06
一句话结论老年患者皮下注射溴莫尼定致低血压与中枢抑制,高剂量纳洛酮逆转中枢抑制和血流动力学不稳定。

报告一例73岁女性青光眼患者故意皮下注射溴莫尼定滴眼液后出现嗜睡、起搏心律60次/分、血压91/24 mmHg(平均动脉压46),无抗高血压药或阿片类药物使用史。因中枢神经系统抑制给予鼻内纳洛酮3 mg,并予静脉补液及递增剂量纳洛酮,需持续输注,精神状态和生命体征改善,入住ICU后12小时内逐渐减停纳洛酮。作者认为高剂量纳洛酮有助于逆转中枢α-2肾上腺素能激动剂过量所致的中枢抑制和血流动力学不稳定。

要点

  • 皮下注射溴莫尼定可致全身中枢α-2肾上腺素能激动剂毒性,表现为中枢抑制、心动过缓和低血压,可类似阿片类中毒综合征。
  • 该73岁女性初始嗜睡、起搏心律60次/分、血压91/24 mmHg、平均动脉压46,予鼻内纳洛酮3 mg后继续静脉补液和递增剂量纳洛酮并持续输注。
  • 纳洛酮持续输注入ICU后12小时内逐渐减停,患者精神状态和生命体征改善。
  • 既往纳洛酮对中枢α-2过量所致中枢抑制的逆转作用不一,本例作者认为高剂量纳洛酮对逆转中枢抑制和血流动力学不稳定有用。

适用人群与场景

  • 故意皮下注射溴莫尼定滴眼液的老年患者;该患者有青光眼、高血压和起搏器植入史,未服用抗高血压药或阿片类药物。

处置流程与药物剂量

  • 因中枢神经系统抑制给予鼻内纳洛酮3 mg。
  • 予静脉补液和递增剂量纳洛酮,并需要持续输注。
  • 入住ICU后纳洛酮在12小时内逐渐减停。

红旗征与不能漏的情况

  • 嗜睡、中枢神经系统抑制伴心动过缓(起搏心律60次/分)和低血压(血压91/24 mmHg,平均动脉压46),需警惕中枢α-2肾上腺素能激动剂过量。

研究设计与关键结果

  • 病例报告:73岁女性皮下注射酒石酸溴莫尼定滴眼液后出现嗜睡、起搏心律60次/分、血压91/24 mmHg(平均动脉压46),予鼻内纳洛酮3 mg、静脉补液及递增剂量纳洛酮并持续输注后精神状态和生命体征改善,入ICU后12小时内减停纳洛酮。
  • 作者指出皮下注射溴莫尼定此前未见报告,本例表现与其他中枢α-2肾上腺素能激动剂中毒相似;既往纳洛酮对中枢α-2过量所致中枢抑制的逆转作用不一,本例高剂量纳洛酮对逆转中枢抑制和血流动力学不稳定有用。

证据类型、等级与局限

  • 病例报告。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为高剂量纳洛酮对逆转溴莫尼定皮下注射所致中枢抑制和血流动力学不稳定有用;中枢α-2肾上腺素能激动剂过量可类似阿片类中毒综合征,表现为中枢抑制、心动过缓和低血压。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Brimonidine is a topical ophthalmic alpha-2 adrenergic agonist solution used to treat glaucoma. The toxidrome includes drowsiness, lethargy, hypotension, bradycardia, and respiratory depression when ingested in infants. We report a case of intentional subcutaneous injection of brimonidine in an elderly patient resulting in hypotension and CNS depression that responded to naloxone. A 73-year-old female with a past medical history significant for glaucoma, hypertension, and indwelling pacemaker presented to the emergency department after injecting her brimonidine tartrate ophthalmic solution subcutaneously (SQ). The patient was not taking any antihypertensive medications or opioids. Initial presentation consisted of lethargy, a paced rhythm of 60 bpm, and blood pressure of 91/24 mmHg with a MAP of 46. Due to central nervous system depression, 3 mg of intranasal naloxone was administered. The patient was treated with intravenous fluids and escalating doses of naloxone and required a continuous infusion. Mental status and vital signs subsequently improved. The patient was admitted to the ICU and naloxone was subsequently weaned over 12 h. Systemic central alpha-2 adrenergic agonist toxicity resulted from SQ brimonidine injection. Central alpha-2 adrenergic agonist overdoses present as sympatholytic effects including CNS depression, bradycardia, hypotension, and may mimic the opioid toxidrome. Brimonidine SQ injection has not previously been reported and this case has similar findings to other central alpha-2 adrenergic agonist poisonings. Naloxone has previously shown variable reversal of CNS depression in central alpha-2 overdose. In this case, high-dose naloxone was useful for reversing CNS depression and hemodynamic instability.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Tobarran N, Kershner E, Chambers A, et al. Systemic toxicity from subcutaneous brimonidine injection successfully treated with naloxone. Am J Emerg Med. 2022. PMID: 35835657. doi:10.1016/j.ajem.2022.07.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。